Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 320-331

  Tabernero, Josep ^a   Van Cutsem, Eric ^b   Lakomý, Radek ^c   Prausová, Jana ^d   Ruff, Paul ^e   Van Hazel, Guy A ^f   Moiseyenko, Vladimir M ^g   Ferry, David R ^h   McKendrick, Joseph J ⁱ   Soussan Lazard, Karen ^j   Chevalier, Soazig ^j   Allegra, Carmen J ^k  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^h RUSSELLS HALL HOSPITAL   (United Kingdom)

ⁱ MONASH UNIVERSITY   (Australia)

^j SANOFI   (France)

^k UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

Aflibercept; Bevacizumab; Metastatic colorectal cancer; Performance status; Subgroup analysis; VEGF Trap

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

EID: 84891831211     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.09.013     Document Type: Article

References (9)

1. American Cancer Society. Cancer facts and figures 2011. < http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-029771.pdf >; 2011 [accessed June 2012].
2. J.S. Rudge, J. Holash, and D. Hylton et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade Proc Natl Acad Sci U S A 104 47 2007 18363 18370
3. W.P. Tew, M. Gordon, and J. Murren et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors Clin Cancer Res 16 1 2010 358 366
4. R. Adam, A. De Gramont, and J. Figueras et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus Oncologist 17 10 2012 1225 1239
5. T.J. Smith, J. Khatcheressian, and G.H. Lyman et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 19 2006 3187 3205
6. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
7. M. Peeters, T.J. Price, and A. Cervantes et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 2010 4706 4713
8. J. Bennouna, J. Sastre, and D. Arnold et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 1 2013 29 37
9. Q.S. Chu Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors Expert Opin Biol Ther 9 2 2009 263 271